

Luis Masana Marn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2772743/luis-masana-marin-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

270
papers

14,275
citations

43
h-index

115
g-index

305
ext. papers

17,596
ext. citations

3.7
avg, IF

5.77
L-index

#	Paper	IF	Citations
270	DNA methylation pattern of hypertriglyceridemic subjects. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2022 , 34, 27-27	0.3	
269	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2022 , 34, 10-10	0.3	
268	HTE 3.0: Knowledge-based systems in cascade for familial hypercholesterolemia detection and dyslipidemia treatment. <i>Expert Systems</i> , 2022 , 39, e12835	2.1	
267	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting.. <i>Advances in Therapy</i> , 2022 , 39, 1857	4.1	1
266	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 775677	5.7	0
265	DNA methylation pattern of hypertriglyceridemic subjects. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021 , 34, 27-27	1.4	0
264	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk.. <i>Frontiers in Physiology</i> , 2021 , 12, 781789	4.6	0
263	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. <i>Diabetes Care</i> , 2021 ,	14.6	4
262	Statistical mediation of the relationships between chronological age and lipoproteins by nonessential amino acids in healthy men.. <i>Computational and Structural Biotechnology Journal</i> , 2021 , 19, 6169-6178	6.8	1
261	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021 ,	1.4	2
260	Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 75, 5-5	0.7	
259	Long-term exposure to PM above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , 2021 , 158, 106930	12.9	7
258	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 1279-1289	3.9	92
257	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , 2021 , 11, 7217	4.9	40
256	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021 , 107, 1369-1375	5.1	13
255	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021 , 33, 138-147	0.3	1
254	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021 , 325, 99-109	3.1	22

253	Triglyceride metabolism and classification of hypertriglyceridemias. <i>Cliica E Investigaci3n En Arteriosclerosis</i> , 2021 , 33 Suppl 2, 1-6	1.4	1
252	Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. <i>Cliica E Investigaci3n En Arteriosclerosis</i> , 2021 , 33 Suppl 1, 53-57	1.4	1
251	Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13610	2.9	3
250	Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 1299-1307	4.5	1
249	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2021 ,	9.5	11
248	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Cliica E Investigaci3n En Arteriosclerosis</i> , 2021 , 33, 138-147	1.4	0
247	Plasma expression of microRNA-425-5p and microRNA-451a as biomarkers of cardiovascular disease in rheumatoid arthritis patients. <i>Scientific Reports</i> , 2021 , 11, 15670	4.9	2
246	Serum glycoproteins A and B assessed by H-NMR in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021 , 330, 1-7	3.1	2
245	Perfil lipoproteico determinado por resonancia magn3tica. El momento de su utilizaci3n cl3nica ha llegado. <i>Revista Espanola De Cardiologia</i> , 2021 , 75, 5-5	1.5	
244	Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	2
243	Evolution of Serum Acute-Phase Glycoproteins Assessed by H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021 , 12, 730691	8.4	0
242	EFFECT OF STATIN THERAPY ON SARS-CoV-2 INFECTION-RELATED. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	43
241	Glycoprotein Profile Assessed by H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
240	Plasma glucose, triglycerides, VLDL, leptin and resistin levels as potential biomarkers for myocardial fat in mice. <i>Cliica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020 , 32, 8-14	0.3	
239	LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models. <i>Circulation Research</i> , 2020 , 127, 778-792	15.7	21
238	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy. <i>Current Cardiology Reports</i> , 2020 , 22, 66	4.2	6
237	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Cliica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020 , 32, 49-58	0.3	
236	Plasma glucose, triglycerides, VLDL, leptin and resistin levels as potential biomarkers for myocardial fat in mice. <i>Cliica E Investigaci3n En Arteriosclerosis</i> , 2020 , 32, 8-14	1.4	4

235	Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. <i>Atherosclerosis</i> , 2020 , 299, 24-31	3.1	13
234	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020 , 32, 183-192	1.4	0
233	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020 , 32, 49-58	1.4	1
232	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020 , 42, e30-e34	1.7	2
231	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020 , 42, e49-e58	1.7	4
230	Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 161-167	1.5	20
229	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020 , 41, 2313-2330	9.5	301
228	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. <i>Atherosclerosis</i> , 2020 , 292, 42-51	3.1	1
227	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 325-332	4	
226	Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 161-167	0.7	1
225	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. <i>JAMA Cardiology</i> , 2020 , 5, 1452-1453	16.2	
224	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2020 , 32, 183-192	0.3	
223	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale [®]). <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2020 , 32, 219-229	0.3	0
222	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale [®]). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020 , 32, 219-229	1.4	2
221	Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms. <i>Biomolecules</i> , 2020 , 10,	5.9	4
220	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019 , 31, 128-139	1.4	13
219	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019 , 287, 89-92	3.1	20
218	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , 2019 , 36, 1786-1811	4.1	22

217	Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, 12-21	12.7	15
216	Assessment of arterial stiffness variables in patients with rheumatoid arthritis: A mediation analysis. <i>Scientific Reports</i> , 2019 , 9, 4543	4.9	9
215	Palmitate decreases migration and proliferation and increases oxidative stress and inflammation in smooth muscle cells: role of the Nrf2 signaling pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 316, C888-C897	5.4	7
214	Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives. <i>Journal of Medical Genetics</i> , 2019 , 56, 711-717	5.8	8
213	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019 , 72, 519-520	0.7	
212	Estimaci3n del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2019 , 72, 519-520	1.5	2
211	Treating dyslipidemia: something more than giving statins. <i>Cl3nica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019 , 31, 119-120	0.3	
210	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	21
209	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	21
208	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Cl3nica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019 , 31, 128-139	0.3	
207	Standards for global cardiovascular risk management arteriosclerosis. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2019 , 31 Suppl 1, 1-43	1.4	1
206	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
205	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Cl3nica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019 , 31, 271-277	0.3	1
204	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2019 , 31, 271-277	1.4	6
203	Low-density lipoprotein net charge is a risk factor for atherosclerosis in lupus patients independent of lipid concentrations. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 480-487	2.3	4
202	Extracellular FABP4 uptake by endothelial cells is dependent on cytokeratin 1 expression. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019 , 1864, 234-244	5	6
201	MicroRNA differential expression shared between rheumatoid arthritis and acute myocardial infarction: an exploratory study. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 886-887	2.2	2
200	Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. <i>Journal of Nutrition</i> , 2018 , 148, 285-297	4.1	7

199	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study. <i>Clinica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2018 , 30, 1-9	0.3	0
198	Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2018 , 30, 170-178	1.4	7
197	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 1010-1017	0.7	4
196	Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 466-468	15.1	9
195	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 292-299.e3	4.9	33
194	Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 279-288	15.1	30
193	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2018 , 270, 117-122	3.1	7
192	N3mero de pacientes candidatos a recibir inhibidores de la PCSK9 seg3n datos de 2,5 millones de participantes de la pr3ctica cl3nica real. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 1010-1017	1.5	17
191	FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018 , 1863, 604-613	5	20
190	The Zero-LDL Hypothesis. Towards Extremely Low LDL Concentrations. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 591-592	0.7	
189	La hip3tesis del LDL cero. Hacia concentraciones de LDL extremadamente bajas. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 591-592	1.5	6
188	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2018 , 30, 1-9	1.4	5
187	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 211-218	4.9	10
186	Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project. <i>Clinica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2018 , 30, 170-178	0.3	0
185	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1482-1492.e3	4.9	14
184	Variables associated with subclinical atherosclerosis in a cohort of rheumatoid arthritis patients: Sex-specific associations and differential effects of disease activity and age. <i>PLoS ONE</i> , 2018 , 13, e0193690	3.7	8
183	Autosomal recessive hypercholesterolemia in Spain. <i>Atherosclerosis</i> , 2018 , 269, 1-5	3.1	15
182	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1452-1462	4.9	7

181	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: The DECOPI project. <i>Atherosclerosis</i> , 2018 , 278, 210-216	3.1	12
180	Characterization of H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory Patterns in Rheumatoid Arthritis. <i>Journal of Proteome Research</i> , 2018 , 17, 3730-3739	5.6	23
179	Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. <i>Molecular Carcinogenesis</i> , 2017 , 56, 208-217	5	68
178	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. <i>Atherosclerosis Supplements</i> , 2017 , 26, 2-15	1.7	22
177	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017 , 38, 2459-2472	9.5	1267
176	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , 2017 , 262, 107-112	3.1	19
175	Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. <i>Journal of Endocrinology</i> , 2017 , 233, R173-R184	4.7	58
174	Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1013-1022	4.9	41
173	Familial hypercholesterolemia in childhood and adolescents: A hidden reality. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017 , 29, 129-140	0.3	
172	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. <i>Clinical Therapeutics</i> , 2017 , 39, 771-786.e3	3.5	35
171	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 687-693	14.6	34
170	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1448-1457	4.9	32
169	New perspectives on CKD-induced dyslipidemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 967-976.4	6.4	21
168	Familial hypercholesterolemia in childhood and adolescents: A hidden reality. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017 , 29, 129-140	1.4	7
167	Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1280-1283	4.9	5
166	Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017 , 29, 278-279	0.3	
165	Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients. <i>Oncologist</i> , 2017 , 22, 1309-1315	5.7	16
164	Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017 , 29, 278-279	1.4	

163	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. <i>Cardiovascular Diabetology</i> , 2016 , 15, 107	8.7	24
162	Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 330-8.e2	4.9	7
161	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2016 , 28, 71-8	1.4	26
160	Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes. <i>Scientific Reports</i> , 2016 , 6, 19249	4.9	18
159	Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 342-3	0.7	3
158	M3xima reducci3n de colesterol unido a lipoprote3nas de baja densidad alcanzable con combinaciones farmacol3gicas. Cuando 50 m3s 20 suma 60. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 342-343	1.5	16
157	Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells. <i>Atherosclerosis</i> , 2016 , 249, 191-9	3.1	28
156	Long-term effects of continuous positive airway pressure treatment on subclinical atherosclerosis in obstructive sleep apnoea syndrome. <i>Medicina Cl3nica (English Edition)</i> , 2016 , 147, 1-6	0.3	
155	Intraabdominal fat redistribution in long-term continuous positive airway pressure treatment in obstructive sleep apnea patients. <i>Medicina Cl3nica (English Edition)</i> , 2016 , 146, 484-487	0.3	
154	APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels. <i>Clinical Science</i> , 2016 , 130, 2053-2059	6.5	10
153	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. <i>Annals of Clinical and Laboratory Science</i> , 2016 , 46, 229-32	0.9	
152	Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. <i>Clinical Science</i> , 2015 , 128, 877-82	6.5	16
151	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. <i>Journal of Lipid Research</i> , 2015 , 56, 737-746	6.3	90
150	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? <i>Atherosclerosis</i> , 2015 , 240, 161-2	3.1	41
149	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. <i>Atherosclerosis</i> , 2015 , 240, 98-104	3.1	19
148	Design and evaluation of standard lipid prediction models based on 1H-NMR spectroscopy of human serum/plasma samples. <i>Metabolomics</i> , 2015 , 11, 1394-1404	4.7	2
147	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015 , 36, 2425-37	9.5	430
146	In Vitro Biocompatibility of Surface-Modified Porous Alumina Particles for HepG2 Tumor Cells: Toward Early Diagnosis and Targeted Treatment. <i>ACS Applied Materials & Interfaces</i> , 2015 , 7, 18600-8	9.5	21

145	New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 2966-74	4.9	25
144	FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015 , 25, 875-80	4.5	4
143	Las Competencias Profesionales de Los Titulados en Medicina Mejoran Con la Introducci3n de un Programa de Simulaci3n Con Pacientes Estandarizados y MINIC-CEX. <i>Procedia, Social and Behavioral Sciences</i> , 2015 , 196, 25-29		
142	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. <i>Atherosclerosis</i> , 2015 , 238, 213-9	3.1	15
141	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. <i>European Journal of Human Genetics</i> , 2015 , 23, 381-7	5.3	10
140	Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 417-25	0.7	6
139	Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition. <i>PLoS ONE</i> , 2015 , 10, e0133875	3.7	12
138	AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression. <i>PPAR Research</i> , 2015 , 2015, 785783	4.3	12
137	Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 824-831.e1	4.9	10
136	Is complying with the recommendations of sodium intake beneficial for health in individuals at high cardiovascular risk? Findings from the PREDIMED study. <i>American Journal of Clinical Nutrition</i> , 2015 , 101, 440-8	7	19
135	The pleiotropic role of HDL in autoimmune diseases. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2015 , 27, 97-106	1.4	8
134	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014 , 232, 346-60	3.1	330
133	Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2014 , 26, 274-84	1.4	10
132	Should we forget about low-density lipoprotein cholesterol?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1228-1229	15.1	10
131	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2014 , 26, 58-65	1.4	4
130	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. <i>Journal of Nutritional Biochemistry</i> , 2014 , 25, 642-6	6.3	19
129	MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2014 , 26, 49-57	1.4	3
128	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 655-66	18.1	357

127	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014 , 15, 1-15	1.7	62
126	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014 , 35, 2146-57	9.5	614
125	Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: the di@bet.es study. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2014 , 26, 107-14	1.4	7
124	Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. <i>Cardiovascular Diabetology</i> , 2013 , 12, 72	8.7	16
123	Akt and ERK/Nrf2 activation by PUFA oxidation-derived aldehydes upregulates FABP4 expression in human macrophages. <i>Atherosclerosis</i> , 2013 , 230, 216-22	3.1	14
122	Pitavastatin in cardiometabolic disease: therapeutic profile. <i>Cardiovascular Diabetology</i> , 2013 , 12 Suppl 1, S2	8.7	16
121	Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2013 , 70, 1-24	10.4	42
120	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. <i>Atherosclerosis</i> , 2013 , 226, 471-5	3.1	16
119	HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?. <i>Atherosclerosis</i> , 2013 , 229, 449-50	3.1	12
118	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013 , 34, 3478-90a	9.5	1551
117	Even low physical activity levels improve vascular function in overweight and obese postmenopausal women. <i>Menopause</i> , 2013 , 20, 1036-42	2.5	12
116	Negative effect of a low-carbohydrate, high-protein, high-fat diet on small peripheral artery reactivity in patients with increased cardiovascular risk. <i>British Journal of Nutrition</i> , 2013 , 109, 1241-7	3.6	11
115	FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. <i>PLoS ONE</i> , 2013 , 8, e81914	3.7	39
114	Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment. <i>Sleep</i> , 2013 , 36, 1831-7	1.1	10
113	Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2012 , 402, 2407-15	4.4	23
112	La adici3n de leche fermentada suplementada con esteroides vegetales mejora el cumplimiento de los cambios en el estilo de vida en los pacientes hipercolesterol3micos. Estudio RECIPE. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2012 , 24, 173-180	1.4	
111	Las concentraciones de Apo-B100 en los pacientes con hipercolesterolemia familiar se asocian a una mayor rigidez arterial. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2012 , 24, 289-296	1.4	
110	FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. <i>Atherosclerosis</i> , 2012 , 222, 229-34	3.1	26

109	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2012 , 222, 449-55	3.1	53
108	Lifestyle Changes Lower FABP4 Plasma Concentration in Patients With Cardiovascular Risk. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 152-157	0.7	
107	Lifestyle changes lower FABP4 plasma concentration in patients with cardiovascular risk. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 152-7	1.5	10
106	Efecto de los cambios terapéuticos del estilo de vida sobre la función endotelial en pacientes con obesidad abdominal. <i>Clínica E Investigación En Arteriosclerosis</i> , 2012 , 24, 3-11	1.4	
105	Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. <i>Cardiovascular Diabetology</i> , 2012 , 11, 72	8.7	51
104	Two variants in the fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension. <i>PLoS ONE</i> , 2012 , 7, e43051	3.7	7
103	Small artery dilation and endothelial markers in cardiovascular risk patients. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 34-41	4.6	10
102	Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trial. <i>PLoS ONE</i> , 2012 , 7, e31103	3.7	31
101	Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. <i>Gynecological Endocrinology</i> , 2011 , 27, 935-9 ^{2.4}		9
100	Análisis funcional de mutaciones en el promotor del LDLR y su relación con la hipercolesterolemia familiar. <i>Clínica E Investigación En Arteriosclerosis</i> , 2011 , 23, 119-124	1.4	
99	FABP4, función endotelial y grosor de la íntima-media carotídeo en pacientes con riesgo cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2011 , 23, 211-218	1.4	
98	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020
97	High-density lipoprotein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. <i>Atherosclerosis</i> , 2011 , 216, 115-9	3.1	24
96	Heterozygous familial hypercholesterolaemic patients have increased arterial stiffness, as determined using the augmentation index. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011 , 18, 1110-6	4	14
95	Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for the characterisation of human plasma lipoproteins. <i>Metabolomics</i> , 2011 , 7, 572-582	4.7	21
94	Functional analysis of LDLR promoter and 5'UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. <i>Human Mutation</i> , 2011 , 32, 868-72	4.7	22
93	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011 , 32, 1345-6 ¹	9.5	793
92	Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 2259-6 ¹	4.1	16

91	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010 , 51, 1173-1178	6.3	10
90	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010 , 31, 2844-53	9.5	1100
89	Concentraciones plasmáticas de FABP4 y evolución del síndrome metabólico. <i>Clínica E Investigación En Arteriosclerosis</i> , 2010 , 22, 247-255	1.4	
88	Pitavastatin - from clinical trials to clinical practice. <i>Atherosclerosis Supplements</i> , 2010 , 11, 15-22	1.7	14
87	APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. <i>Atherosclerosis</i> , 2010 , 209, 201-5	3.1	25
86	Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2010 , 213, 329-31	3.1	47
85	Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los índices aterogénicos en prevención cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2010 , 22, 25-32	1.4	5
84	Effect of the long-term regular intake of virgin olive oil on the phenolic metabolites in human fasting plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 53, 68-74	3.5	8
83	Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. <i>Clinical Nutrition</i> , 2010 , 29, 373-80	5.9	76
82	Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. <i>Journal of Nutritional Biochemistry</i> , 2010 , 21, 518-25	6.3	48
81	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010 , 51, 1173-8	6.3	17
80	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2009 , 204, 345-7	3.1	17
79	Prox-1 and FOXC2 gene expression in adipose tissue: A potential contributory role of the lymphatic system to familial combined hyperlipidaemia. <i>Atherosclerosis</i> , 2009 , 206, 343-5	3.1	16
78	Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. <i>Vascular Health and Risk Management</i> , 2009 , 5, 757-65	4.4	358
77	Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2008 , 102, 1187-93, 1193.e1	3	120
76	Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. <i>Clinical Therapeutics</i> , 2008 , 30, 84-97	3.5	15
75	Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 380-7	4.5	38
74	The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. <i>Atherosclerosis</i> , 2008 , 199, 147-53	3.1	28

73	Asociaci3n entre el gen de la celular retinoic acid binding protein (CRABP2) y valores elevados de colesterol unido a lipoprote3nas de baja densidad. <i>C3nica E Investigaci3n En Arteriosclerosis</i> , 2008 , 20, 48-54	1.4	
72	El gen de la apolipoprote3na A5 se expresa en el intestino humano. <i>C3nica E Investigaci3n En Arteriosclerosis</i> , 2008 , 20, 129-134	1.4	
71	Los 3cidos grasos poliinsaturados disminuyen la expresi3n in vitro de la prote3na NPC1L1, clave en la absorci3n intestinal de colesterol. <i>C3nica E Investigaci3n En Arteriosclerosis</i> , 2008 , 20, 200-206	1.4	
70	The apolipoprotein A5 gene -1131T-->C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 453-7	5.9	15
69	Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. <i>Clinical Chemistry</i> , 2008 , 54, 181-7	5.5	40
68	Retinoic acid induces PGI synthase expression in human endothelial cells. <i>Journal of Lipid Research</i> , 2008 , 49, 1707-14	6.3	17
67	Influence of inflammatory variables on intima-media thickness. <i>Stroke</i> , 2008 , 39, e16	6.7	
66	Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. <i>Journal of Lipid Research</i> , 2008 , 49, 1746-51	6.3	69
65	Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. <i>European Journal of Nutrition</i> , 2008 , 47, 32-9	5.2	60
64	Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids. <i>IUBMB Life</i> , 2008 , 60, 757-64	4.7	74
63	Tumor necrosis factor-alpha -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1697-703	4.1	23
62	Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH. <i>Revista Espanola De Cardiologia</i> , 2007 , 60, 251-258	1.5	2
61	Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 615-20	5.9	9
60	Carotid intima-media thickness course in HIV-infected patients: beyond classical cardiovascular risk factors. <i>Aids</i> , 2007 , 21, 1989-90	3.5	1
59	Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene - 1131T>C variant and associations with plasma lipids and lipid peroxidation. <i>Journal of Lipid Research</i> , 2007 , 48, 2506-13	6.3	16
58	Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 829-34	5.9	2
57	Effects of soluble fiber (Plantago ovata husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. <i>American Journal of Clinical Nutrition</i> , 2007 , 85, 1157-63	7	38
56	Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. <i>Molecular Genetics and Metabolism</i> , 2007 , 92, 243-8	3.7	18

55	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. <i>Atherosclerosis</i> , 2007 , 194, 175-81	3.1	56
54	La grasa saturada en la dieta disminuye la expresi3n hep3tica de APOA5 en ratones deficientes en apo E. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2007 , 19, 22-29	1.4	
53	Efecto del 3ido 13-cis-retinoico sobre el perfil de expresi3n g3nica de c3lulas HUVEC (human umbilical vein endothelial cells) determinado por microarray. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2007 , 19, 129-135	1.4	
52	The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. <i>Stroke</i> , 2007 , 38, 2477-84	6.7	61
51	Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 39-58	4	37
50	Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. <i>Clinical Chemistry</i> , 2006 , 52, 1914-9	5.5	43
49	HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. <i>Cytokine</i> , 2006 , 34, 51-5	4	44
48	Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2006 , 20, 1675-7	3.5	50
47	Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. <i>Clinical Therapeutics</i> , 2005 , 27, 174-84	3.5	55
46	The stromal derived factor-1 mutated allele (SDF1-3PA) is associated with a lower incidence of atherosclerosis in HIV-infected patients. <i>Aids</i> , 2005 , 19, 1877-83	3.5	17
45	Additive effects of the PPARgamma, APOE, and FABP-2 genes in increasing daylong triglycerides of normolipidemic women to concentrations comparable to those in men. <i>Clinical Chemistry</i> , 2005 , 51, 864-71	5.5	13
44	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. <i>Aids</i> , 2005 , 19, 341-2	3.5	27
43	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004 , 42, 384-6	5.9	6
42	Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. <i>Circulation</i> , 2004 , 110, 2204-9	16.7	104
41	Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (<i>Argania spinosa</i>). <i>Clinical Nutrition</i> , 2004 , 23, 1159-66	5.9	105
40	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. <i>European Journal of Pharmacology</i> , 2004 , 496, 205-12	5.3	5
39	Aldehydes mediate tissue factor induction: a possible mechanism linking lipid peroxidation to thrombotic events. <i>Journal of Cellular Physiology</i> , 2004 , 198, 230-6	7	9
38	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1437-45	2.5	76

37	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2004 , 18, 819-21	3.5	38
36	Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003 , 6, 177-87	3.8	40
35	High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. <i>Aids</i> , 2003 , 17, 1173-8	3.5	30
34	Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene. <i>Journal of Human Genetics</i> , 2003 , 48, 199-203	4.3	15
33	Prevalence of and predictors of bicuspid aortic valves in patients with dilated aortic roots. <i>American Journal of Cardiology</i> , 2003 , 91, 619-22	3	29
32	Cytotoxic effects of the lipid peroxidation product 2,4-decadienal in vascular smooth muscle cells. <i>Atherosclerosis</i> , 2003 , 169, 245-50	3.1	22
31	Two novel single nucleotide polymorphisms in the promoter of the cellular retinoic acid binding protein II gene (CRABP-II). <i>Molecular and Cellular Probes</i> , 2003 , 17, 21-3	3.3	10
30	HDL derived from the different phases of conjugated diene formation reduces membrane fluidity and contributes to a decrease in free cholesterol efflux from human THP-1 macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2003 , 1633, 143-8	5	25
29	The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003 , 41, 517-21	5.9	32
28	Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. <i>The American Journal of Geriatric Cardiology</i> , 2003 , 12, 225-31		29
27	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. <i>Aids</i> , 2002 , 16, 1383-9	3.5	76
26	Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. <i>Atherosclerosis</i> , 2002 , 164, 45-56	3.1	52
25	Micronutrientes en la infección por el virus de la inmunodeficiencia humana y su relación con la respuesta inflamatoria. <i>Medicina Clínica</i> , 2002 , 119, 765-769	1	3
24	Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. <i>BMJ: British Medical Journal</i> , 2001 , 322, 603-5		56
23	Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2761-7		114
22	Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling. <i>Atherosclerosis</i> , 2001 , 155, 99-112	3.1	13
21	Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 721-30	5.9	60
20	Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. <i>Metabolism: Clinical and Experimental</i> , 2000 , 49, 942-9	12.7	25

19	Molecular requirements in the recognition of low-density lipoproteins (LDL) by specific platelet membrane receptors. <i>Thrombosis Research</i> , 2000 , 99, 51-60	8.2	5
18	Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants. <i>Atherosclerosis</i> , 2000 , 152, 317-25	3.1	50
17	Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis. <i>Molecular and Cellular Biochemistry</i> , 1999 , 198, 57-60	4.2	10
16	Mechanisms for regulating platelet high density lipoprotein type3 binding sites: evidence that binding sites are downregulated by a protein kinase C-dependent mechanism. <i>Thrombosis Research</i> , 1999 , 94, 33-44	8.2	12
15	A comparison of lifestyle, genetic, bioclinical and biochemical variables of offspring with and without family histories of premature coronary heart disease: the experience of the European Atherosclerosis Research Studies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1999 , 6, 183-8		6
14	Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 1999 , 40, 426-431	6.3	9
13	Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. <i>Atherosclerosis</i> , 1998 , 140, 155-9	3.1	33
12	Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. <i>Aids</i> , 1998 , 12, 1965-72	3.5	16
11	Oleic acid rich diet protects against the oxidative modification of high density lipoprotein. <i>Free Radical Biology and Medicine</i> , 1997 , 22, 1037-45	7.8	62
10	Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-alpha secretion by THP-1 human macrophages. <i>Free Radical Biology and Medicine</i> , 1997 , 23, 658-67	7.8	30
9	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. <i>Cardiovascular Drugs and Therapy</i> , 1997 , 11, 653-8	3.9	6
8	Prevalence of dementia in a semi-rural population of Catalunya, Spain. <i>Neuroepidemiology</i> , 1996 , 15, 33-41	5.4	21
7	Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting from alcohol abuse: effects of alcohol intake cessation. <i>Journal of Hepatology</i> , 1994 , 21, 704-9	13.4	10
6	In vitro oxidised HDL is recognized by the scavenger receptor of macrophages: implications for its protective role in vivo. <i>Atherosclerosis</i> , 1994 , 105, 179-89	3.1	41
5	Low-density lipoprotein metabolism in rats treated with cyclosporine. <i>Metabolism: Clinical and Experimental</i> , 1993 , 42, 678-83	12.7	28
4	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. <i>Clinical Science</i> , 1992 , 83, 695-700	6.5	67
3	Interaction of oxidized low density lipoproteins with both apo B,E and scavenger receptors. A model for its production in vitro. <i>Clinica Chimica Acta</i> , 1992 , 210, 93-108	6.2	1
2	Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. <i>American Journal of Cardiology</i> , 1991 , 68, 863-7	3	16

- 1 Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. *New England Journal of Medicine*, **1990**, 323, 579-84 59.2 224